In this contribution, graphene oxide/gold nanoparticle (GO/AuNPs) hybrids were in situ fabricated through a green one-pot procedure by using tyrosine as an environment friendly and biocompatible reducing agent, which can be used as highly efficient surface enhanced Raman scattering (SERS) substrates with the enhancement factor at 3.8 × 103. The as-prepared GO/AuNPs hybrids have good biocompatibility, providing the prospect of applications for biomedicine determinations. In addition, taking the advantages of the electromagnetic and chemical enhancement mechanism and the high affinity of GO and AuNPs towards positive dyes, a sensitive, selective and label-free malachite green (MG) detection method was demonstrated. The SERS measurement showed that the minimum detection concentration of MG in water was as low as 2.5 μmol L−1 with a linear response range from 2.5 to 100 μmol L−1 (R2 = 0.996). Moreover, this method can be applied to detect MG in a fishery water sample with satisfactory results.
Graphene oxide (GO) introduced to enhance the fluorescence anisotropy (FA) of fluorogens was identified to be effective for highly sensitive and selective detection of metal ions through an anisotropy DNAzyme-based strategy.
Graphene oxide (GO) exhibits distinctive Raman scattering features for its high frequency D (disordered) and tangential modes (G-band), which are characteristically sharp at 1580 cm−1 and 1350 cm−1, respectively, but are too weak for sensitive quantitation purposes. By depositing silver nanoparticles on the surface of GO in this contribution, both D and G bands of GO become enhanced. The enzyme label of this method controls the dissolution of silver nanoparticles on the surface of GO through hydrogen peroxide which is produced by the oxidation of the enzyme substrate. With the dissolution of the silver nanoparticles a greatly decreased SERS signal of GO was obtained. This strategy involves dual signal amplification of the enzyme and nanocomposites to improve the detection sensitivity. As a proof of concept, prostate specific antigen (PSA), a biomarker for prostate cancer, is successfully detected as a target by forming a sandwich structure in immunoassay. The SERS immunoassay possesses excellent analytical performance in the range 0.5 pg mL−1 to 500 pg mL−1 with a limit of detection of 0.23 pg mL−1, making the detection of PSA serum samples from prostate cancer patients satisfactory, demonstrating that the sensitive enzyme-assisted dissolved AgNPs SERS immunoassay of PSA has potential applications in clinical diagnosis.